GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sanara MedTech Inc (NAS:SMTI) » Definitions » Retained Earnings

Sanara MedTech (Sanara MedTech) Retained Earnings : $-28.04 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Sanara MedTech Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Sanara MedTech's retained earnings for the quarter that ended in Dec. 2023 was $-28.04 Mil.

Sanara MedTech's quarterly retained earnings declined from Jun. 2023 ($-26.74 Mil) to Sep. 2023 ($-27.80 Mil) and declined from Sep. 2023 ($-27.80 Mil) to Dec. 2023 ($-28.04 Mil).

Sanara MedTech's annual retained earnings declined from Dec. 2021 ($-15.24 Mil) to Dec. 2022 ($-23.40 Mil) and declined from Dec. 2022 ($-23.40 Mil) to Dec. 2023 ($-28.04 Mil).


Sanara MedTech Retained Earnings Historical Data

The historical data trend for Sanara MedTech's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanara MedTech Retained Earnings Chart

Sanara MedTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.68 -7.03 -15.24 -23.40 -28.04

Sanara MedTech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.40 -24.91 -26.74 -27.80 -28.04

Sanara MedTech Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Sanara MedTech  (NAS:SMTI) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Sanara MedTech (Sanara MedTech) Business Description

Traded in Other Exchanges
N/A
Address
1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel.
Executives
Eric D Major director 751 MILLER DRIVE SE, LEESBURG VA 20175
Zachary B. Fleming officer: President - Surgical Div. 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Shawn M. Bowman officer: President - Wound Care Div. 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Rebecca E Mcmahon officer: President - R&D 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Sara N Ortwein director 5959 LAS COLINAS BOULEVARD, IRVING TX 75039-2298
Robert Andrew Desutter director 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Eric D Tanzberger director 1929 ALLEN PARKWAY, HOUSTON TX 77219
Christopher A. Morrison officer: President - Telehealth Svcs. 1200 SUMMIT AVENUE, SUITE 414, FORT WORTH TX 76102
Roszell Iii Mack director 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Cgi Cellerate Rx, Llc 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Catalyst Rochal, Llc 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Bradley J. Gurasich 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
J Michael Carmena director, officer: Principal Executive Officer 1200 SUMMIT AVE STE 414, FORT WORTH TX 76102
Michael D. Mcneil officer: Chief Financial Officer 1200 SUMMIT AVE, STE 414, FORT WORTH TX 76102
Catalyst Group, Inc. 10 percent owner 1375 ENCLAVE PARKWAY, HOUSTON TX 77077